Pharmaceutical companies Eli Lilly and Novo Nordisk have reached pricing agreements with the Trump administration concerning their weight loss medications. These deals are intended to lower the cost of several drugs for consumers, introducing new pricing structures for both direct purchases and Medicare beneficiaries.
Under the "TrumpRx" program, the monthly prices for medications such as Ozempic and Wegovy are set to decrease to $350, down from their previous ranges of $1,000 to $1,350. Additionally, if approved, drugs like Zepbound and Orforglipron are projected to be priced at an average of $346 per month, a reduction from approximately $1,086. Future orally administered GLP-1 drugs, upon approval, would have an initial dose price of $150 monthly through TrumpRx.
For Medicare enrollees, the prices for specific medications including Ozempic, Wegovy, Mounjaro, and Zepbound will be $245. The Trump administration characterized these agreements as a significant benefit for American patients, while executives from both pharmaceutical firms highlighted their commitment to accessible medicines and the collaborative nature of the agreements.
Source: https://www.livemint.com/news/us-news/eli-lilly-novo-nordisk-to-lower-obesity-drug-cost-strike-pricing-deal-with-trump-triumph-for-american-patients-11762450065631.html